Nutrition Notes: Antioxidants During Cancer Treatment? Kansas City infoZine, MO - By guarding cells against DNA damage, antioxidants play an important role in the cancer process. However, while free radicals can pose a health risk, ...
?Lipstick? Fans? Delayed Gratification New York Times, United States - The biggest strike against the show may be that it has been hard for viewers to find. It began the season on Wednesday nights and was later moved to Fridays ...
College Student Launches Free Homework Help Web Site PR Web (press release), WA - The premise of the site, which is absolutely free, is that all students have strong and weak subjects and they may pose questions on the site regarding ...
Internet can pose a very real health risk The Times, South Africa - As I discovered, a search for ?nausea? turns out results like pregnancy and cancer in equal measure. Unlike well-trained, real-life doctors, the Internet ...
Transfusing Anemic Cancer Patients Boosts Clot Risk Washington Post, United States - Nov 28, 2008 The researchers said their findings pose a dilemma for doctors who want to prevent blood clots, one of the leading causes of illness and death in cancer...
Preservative in beauty products may pose health risk Northwest Cable News, OR - Nov 21, 2008 As a public service announcement from Cornell University explains, long-term exposure to parabens can increase your risk for breast cancer, ...
Ashford community lends support to families in need Dothan Eagle, AL - Mary McGriff, left, and Marci Harrison pose with a picture of Hannah Harrison in the office at Ashford High School. Hannah, who will be three in December, ...
Dry Utah isn't the place for nuclear power StandardNet, Utah - Contrary to allegations that uranium and plutonium in spent fuel elements pose a problem because of million-year half-lives, they are separated from fission ...
Providing Medicines For The Poor Chemical & Engineering News - And these diseases pose additional and particular challenges to discovery and development of medicines and vaccines. Among them is designing and conducting ...
Who transmits HIV? Jakarta Post, Indonesia - When the epidemic began in the early 1980s, AIDS was known as the disease of homosexuals and was referred to as "the gay cancer" or "the gay plague". ...
Source: Google News
Recent News and Articles on the Keywords: cancer + web + 0.30 Related to the article below (Last Update: 8/5/2008)
Progress Energy Increases 2008 Production Guidance istockAnalyst.com, OR - Jul 31, 2008 Mr. Fred Coles passed away after a long and courageous battle with cancer. He was a member of Progress' Board since inception and contributed his wealth of ...TSE:PGX.UN
Breast and Ovarian Cancer Risks Due to Inherited Mutations in BRCA1 and BRCA2 - MC King, JH Marks, JB Mandell - Science, 2003 - sciencemag.org ... or possibly that you are using a browser that does not support current Web standards. ...
any relative with breast cancer, 134, 0.14, 0.06, 0.10, 0.30, 4.1, <10 -6. ...
Web-Based proactive system to improve breast cancer screening R Chaudhry, SM Scheitel, EK McMurtry, DJ Leutink, … - Arch Intern Med, 2007 - Am Med Assoc ... A Web-based system (PRECARES [PREventive CAre REminder System ... man- age and schedule
breast cancer screening for ... 001 Other government vs contract 0.30 .003 Mayo ... -
Fertility outcomes in young women with breast cancer: A Web-based survey AH Partridge, S Gelber, J Peppercorn, E Sampson, M … - ASCO Meeting Abstracts, 2004 - meeting.ascopubs.org ... young women with breast cancer: A Web-based survey. ... a multivariate model, pregnancy
after breast cancer was associated ... age >35, OR 0.30, p=0.002), longer time ...
[CITATION] Fertility outcomes in young women with breast cancer: A Web-based survey. P View, E Page, O Template, S Workflow
Cancer Statistics, 2007 - A Jemal, R Siegel, E Ward, T Murray, J Xu, MJ Thun - CA: A Cancer Journal for Clinicians, 2007 - Am Cancer Soc ... Michael Cancer Statistics, 2007 This information is current as of January 30, 2007
http://caonline.amcancersoc.org/cgi/content/full/57/1/43 the World Wide Web...
[PDF]Beyond the commons: Investigating the value of personalizing web search - J Teevan, ST Dumais, E Horvitz - Proceedings of the Workshop on New Technologies for …, 2005 - adiret.cs.uni-magdeburg.de ... to be of general interest (eg, cancer, Bush, Web search ... of -0.81, which drops off
substantially to -0.30 for positions ... While Web search engines do a good job of ...
… and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer - E Sato, SH Olson, J Ahn, B Bundy, H Nishikawa, F … - Proceedings of the National Academy of Sciences, 2005 - National Acad Sciences ... The interrelationship between subpopulations of TILs and expression of cancer testis
antigens ... of 74 and 25 months, respectively (hazard ratio = 0.30; CI = 0.16 ...
Cancer screening guidelines - R Zoorob, R Anderson, C Cefalu, M Sidani - Am Fam Physician, 2001 - aafp.org ... The lifetime probability of developing testicular cancer is 0.30 percent and ... September
21, 2000, from the World Wide Web: http://www.cancer.org/statistics ... -
Source: Google Scholar
Study: Cancer Drug May Pose Heart Danger
WASHINGTON (AP) -- A successful cancer-fighting drug may also damage the heart, although a researcher says leukemia patients who need Gleevec should not abandon it.
While effectively treating cancer, Gleevec can lead to heart failure in some patients, said Dr. Thomas Force, who teaches medicine at Jefferson Medical College of Thomas Jefferson University in Philadelphia.
His study, published Sunday in the online edition of the journal Nature Medicine, was prompted by reports that 10 patients taking Gleevec for chronic myelogenous leukemia developed severe congestive heart failure.
Gleevec, sold under the Glivec in some countries, had worldwide sales of $1.2 billion in the first six months of this year, according to the manufacturer, Novartis Pharmaceuticals Corp.
"Gleevec is a wonderful drug and patients with these diseases need to be on it. It's a lifesaving drug for sure," Force said in a telephone interview.
"This is not a Vioxx situation," Force added, referring to Merck & Co.'s painkiller that was pulled from the market because of heart side effects.
Force said he is trying to call attention to the fact that Gleevec and other similar drugs coming along could have significant effects on the heart and that doctors need to be aware of this and watch for symptoms. These patients can be helped with heart treatment, he said.
Novartis cited the limited data and said further research was needed to better understand the relationship between such studies and their potential impact on monitoring patients who are on the drug.
The company said in a written statement that the prescribing information with the drug includes data on heart problems. In addition, the drug maker said clinical trials and postmarketing safety data have shown that the incidence of heart failures among people taking drug is "extremely rare."
Novartis said Force's work does not change "the positive benefit/risk ratio of Glivec for thousands of patients being treated for cancer and other life-threatening diseases."
Force said the 10 patients with heart failure were taking Gleevec at the University of Texas' M.D. Anderson Cancer Center in Houston and had no heart problems before going on the drug.
He said doctors took baseline measures of the patients' left ventricular heart function and determined that heart failure developed in these patients between two months and 14 months after they began Gleevec.
Dr. Jean-Bernard Durand of M.D. Anderson discussed these cases with Force at a meeting and suggested they try to determine the cause of this problem, Force said.
Gleevec targets three specific proteins, including one called ABL.
In chronic myelogenous leukemia, genes known as ABL and BCR become fused and produce a hybrid BCR-ABL enzyme that is always active. The overactive BCR-ABL, in turn, drives the excessive proliferation of white blood cells that is the hallmark of leukemia.
Using viruses that produced for normal ABL and a Gleevec-resistant mutant in laboratory studies and in mice, the researchers found that Gleevec inhibited the normal enzyme but not the mutant, and the mutant ABL "rescued" heart cells from the toxic effects of Gleevec.
The research was supported by the National Heart, Lung and Blood Institute, the Leukemia and Lymphoma Society, the Finnish Heart Foundation and the Paavo Nurmi Foundation.
